Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) today announces that the company is strengthening its organization by creating an Investor Relations and Communications function. Christina Malmberg Hägerstrand has been appointed Vice President and Head of Investor Relations and Communications, she joins Xspray Pharma in January 2022.

“With the development of Xspray Pharma and the initial phase of commercialization, the need to communicate with various stakeholders has grown significantly. I am very pleased that Christina has chosen to accept this new position. Her experience from global listed companies and heavily regulated sectors in combination with a solid academic background means we are now ready to implement a more strategic approach in the development of the company's communication and investor relations going forward”, says Per Andersson, CEO Xspray Pharma.

With extensive experience in corporate communication, media relations and financial communication, Christina Malmberg Hägerstrand joins from her current role as Director of External Communication at AstraZeneca AB. She has previously held positions as Head of Communications at Nasdaq Nordic and Baltic and Head of External Communications at Alecta.

Christina holds an LL.M. in Law from Stockholm University. She is also a trained journalist and has worked at Dagens Industri and news agency Infront Direkt.

“I am proud to have been entrusted to take Xspray Pharma to the next level in strategic communication and investor relations. The company has an exciting business concept and product portfolio, now Xspray Pharma is in a phase where communication will play a crucial role. I look forward to contributing to the company's continued success", says Christina Malmberg Hägerstrand.

Christina will join Xspray Pharma on January 10, 2022 and will be part of the executive team.